Overview

A Study of TX000045 in Patients With Pulmonary Hypertension Secondary to Heart Failure With Preserved Ejection Fraction (the APEX Study)

Status:
RECRUITING
Trial end date:
2026-11-20
Target enrollment:
Participant gender:
Summary
TX000045-003 is a double-blind, randomized, parallel group, placebo-controlled, proof- of-concept (POC) study, evaluating 2 dose regimens of TX000045 over the course of a 24-week treatment period (the APEX study).
Phase:
PHASE2
Details
Lead Sponsor:
Tectonic Therapeutic